Showing 2351-2360 of 18625 results for "".
Improving the Prognoses of Multiple Myeloma
https://reachmd.com/programs/clinicians-roundtable/improving-the-prognoses-of-multiple-myeloma/3009/Advances in multiple myeloma therapy are suppressing the dreaded expectations of a daunting disease. How are the latest treatment modalities presenting new avenues for cancer therapy? How can we work to improve our awareness of the changing face of multiple myeloma? Dr. James Berenson, founding presSelecting Patients for Novel Breast Cancer Imaging Modalities: The Role of AI
https://reachmd.com/programs/project-oncology/selecting-patients-for-novel-breast-cancer-imaging-modalities-the-role-of-ai/26408/Here’s how AI risk assessments may be used to identify which patients should be screened for breast cancer using novel imaging modalities.Controlling the Itch in Prurigo Nodularis
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/controlling-the-itch-in-prurigo-nodularis/37169/Raja Sivamani, MD, MS, AP, an integrative dermatologist and Adjunct Associate Professor of Clinical Dermatology at the University of California, Davis, discusses what he says is the biggest unmet need in prurigo nodularis patient care.Enhancing IgAN Care: The Importance of a Proactive Approach
https://reachmd.com/programs/clinicians-roundtable/enhancing-igan-care-the-importance-of-a-proactive-approach/37213/Although IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world, it’s easy to miss and can lead to irreversible kidney damage, underscoring the importance of proactively identifying, monitoring, and treating patients. That’s why Dr. Gates Colbert speaks with Dr. Suneel UdaEpigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
https://reachmd.com/programs/neurofrontiers/epigenetic-immune-signatures-in-alzheimers-implications-for-diagnosis-and-therapy/36464/Patients with Alzheimer's disease—especially APOE4 carriers—show distinct epigenetic immune alterations that may influence disease progression, treatment response, and side effect risk. In this episode, Dr. David Gate, an Assistant Professor of Behavioral Neurology at Northwestern University, divesModerna’s 2024–2025 COVID-19 Vaccine: Composition Updates and Interim Effectiveness Data
https://reachmd.com/programs/clinicians-roundtable/modernas-20242025-covid-19-vaccine-composition-updates-and-interim-effectiveness-data/35462/Through its antigenic and operational updates, the 2024–2025 SPIKEVAX® COVID-19 vaccine has demonstrated moderate protection against current variants. Learn about the vaccine’s new composition as well as its interim effectiveness data with this in-depth review.Delivering Guideline-Based Hepatocellular Carcinoma Care with an Interactive Tool
https://reachmd.com/programs/project-oncology/delivering-guideline-based-hepatocellular-carcinoma-care-with-an-interactive-tool/26320/Learn about a tool that can help clinicians implement the latest guidelines when diagnosing and treating patients with hepatocellular carcinoma.Elderly Patients with IBD: Management Strategies and Care
https://reachmd.com/programs/gi-insights/elderly-patients-with-ibd-management-strategies-and-care/18101/What are some challenges that arise when diagnosing elderly patients with IBD? Find out here.The Updated Role of Non-Invasive Biomarkers in MASLD
https://reachmd.com/programs/gi-insights/the-updated-role-of-non-invasive-biomarkers-in-masld/15980/What is the role of non-invasive biomarkers in MASLD? Here’s the AGA’s clinical practice update.What’s New in Infectious Diseases? Takeaways from IDWeek 2023
https://reachmd.com/programs/clinicians-roundtable/whats-new-in-infectious-diseases-takeaways-from-idweek-2023/16139/What’s happening in the field of infectious diseases, and how can this new research affect patient care in the future?